Synthesis and characterization of CGP-12177-NBD: a fluorescent β-adrenergic receptor probe
References (19)
- et al.
J. Biol. Chem.
(1983) - et al.
FEBS Lett.
(1984) - et al.
Eur. J. Pharmacol.
(1985) - et al.
J. Biol. Chem.
(1982) - et al.
J. Biol. Chem.
(1985) - et al.
Biochim. Biophys. Acta
(1961) - et al.
Anal. Biochem.
(1983) - et al.
Biochem. Pharmacol.
(1987) - et al.
FEBS Lett.
(1981)
There are more references available in the full text version of this article.
Cited by (16)
The chronological evolution of fluorescent GPCR probes for bioimaging
2023, Coordination Chemistry ReviewsFluorescent approaches for understanding interactions of ligands with G protein coupled receptors
2014, Biochimica et Biophysica Acta - BiomembranesPreviously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action
2011, Trends in Pharmacological SciencesCitation Excerpt :Perhaps the disadvantages of tissue autofluorescence – relatively low receptor expression in native tissues, difficulties in quantifying fluorescent ligand binding and technical aspects of the fluorescent properties of these early fluorophores – all contributed to the controversy over the data [29]. In subsequent years, fluorescent derivatives of several β-blockers were synthesized [33], including CGP-12177 [34], a hydrophilic and selective β-adrenoceptor ligand. The most successful was BODIPY CGP-12177, which, at human β2-adrenoceptors, had a KD of 290 pM compared to 200 pM for [3H]CGP [35].
The β-adrenoceptors
1993, New Comprehensive BiochemistrySynthesis and characterization of 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled fluorescent opioids
1992, Biochemical Pharmacology
Copyright © 1988 Published by Elsevier Masson SAS